The Peptide Report
Inside the quiet rise of an 'exercise mimetic' compound that's reshaping how high performers think about metabolism, mitochondria, and energy. Here's what the research actually shows — and why the conversation matters now.
Silicon Valley founders are quietly stacking a new class of mitochondrial-targeting compounds to sustain output without another stimulant. Here's the science behind the SLU-PP-332 conversation — and why it's becoming the executive performance supplement of 2026.
